Affiliation:
1. Institute of Experimental Internal Medicine Otto von Guericke University Magdeburg Germany
2. Department of Drug Design and Target Validation MWT Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter Halle Germany
Abstract
AbstractUbiquitin‐specific proteases represent a family of enzymes that catalyze the cleavage of ubiquitin from specific substrate proteins to regulate their activity. USP48 is a rarely studied USP, which has recently been linked to inflammatory signaling via regulation of the transcription factor nuclear factor kappa B. Nonetheless, a crystal structure of USP48 has not yet been resolved and potent inhibitors are not known. We screened a set of 14 commercially available USP inhibitors for their activity against USP48 and identified the USP2 inhibitor “ML364” as a candidate for further optimization. Using a ligand‐based approach, we derived and synthesized a series of ML364 analogs. The IC50 concentrations of the new compounds to inhibit USP48 were determined in a deubiquitinylase activity assay by measuring the fluorescence intensity using tetra‐ubiquitin rhodamine110 as substrate. A compound containing a carboxylic acid functionalization (17e) inhibited USP48 activity toward tetra‐ubiquitin rhodamine110 with an IC50 of 12.6 µM. Further structure‐based refinements are required to improve the inhibition activity and specificity.
Subject
Drug Discovery,Pharmaceutical Science